Early Use of Automated Insulin Delivery May Protect Against Diabetic Retinopathy Progression in Type 1 Diabetes: Study
New Zealand: A new study published in Diabetes Technology & Therapeutics offers reassuring evidence that short-term use of automated insulin delivery (AID) systems is generally safe for diabetic retinopathy (DR) in people with type 1 diabetes, even amid rapid glycaemic improvements.
Diabetic retinopathy is a common and potentially serious complication of diabetes, and concerns have been raised that rapid improvements in blood glucose control, particularly in individuals with longstanding diabetes, may lead to early worsening of diabetic retinopathy (EWDR). Since automated insulin delivery systems are known to bring about swift and significant improvements in glycemic control, it becomes essential to evaluate their safety in this context.
To address this concern, Matilda M.E. Johansson, Department of Women’s and Children’s Health, University of Otago, Dunedin, New Zealand, and colleagues conducted a study to assess short-term outcomes of diabetic retinopathy in individuals aged 13 years and older with type 1 diabetes who had been using AID systems for a minimum of six months.
For this purpose, the researchers conducted a retrospective observational study across four centers, drawing participants from hospital databases in Dunedin and Christchurch, New Zealand, as well as from two research studies based in Auckland, New Zealand, and Perth, Australia. They gathered demographic and clinical information, along with diabetic retinopathy grading data before and after the initiation of AID, and performed statistical analyses to evaluate any changes in DR status over time.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.